

# STN SEARCH TRANSCRIPT 10/502,255

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspal623zct

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEMS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEMS 2 "Ask CAS" for self-help around the clock  
NEMS 3 New STN Analyst pricing effective March 1, 2006  
NEMS 4 STN Analyst \$500 visualization usage credit offered  
NEMS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEMS 6 MAY 11 KOREAPAT updates resume  
NEMS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEMS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
NEMS 9 MAY 30 USPATFUL/USPATZ  
NEMS 10 The E-term thesaurus is now available in CA/CAPLUS  
NEMS 11 The first reclassification of IPC codes now complete in INPADOC  
NEMS 12 JUN 26 TULSA/TULSAZ reloaded and enhanced with new search and  
NEMS 13 JUN 28 and display fields  
NEMS 14 JUN 28 Price changes in full-text patent databases EFPULL and PCFPULL  
NEMS 15 JUN 11 CHEMSAFE reloaded and enhanced  
NEMS 16 JUN 14 ESTA enhanced with Japanese patents  
NEMS 17 JUN 14 Coverage of Research Disclosure reinstated in DWPI  
NEMS 18 JUN 19 INSPEC enhanced with 1898-1968 archive  
NEMS 19 AUG 09

NEMS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEMS HOURS STN Operating Hours Plus Help Desk Availability  
NEMS LOGIN Welcome Banner and News Items  
NEMS IPC8 For general information regarding STN implementation of IPC 8  
NEMS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 13:16:32 ON 24 AUG 2006

=> FILE REG COST IN U.S. DOLLARS SINCE FILE ENTRY SESSION TOTAL  
FULL ESTIMATED COST 0.42 0.42  
FILE 'REGISTRY' ENTERED AT 13:17:28 ON 24 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4  
DICTIONARY FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH JUNE 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regrprops.html>

=> Uploading C:\Program Files\Stnexp\Queries\SUBSTANCE P PIPERIDINES.str



chain nodes :  
25 30 31 32  
ring nodes :  
1 2 3 4 5 6 9 10 11 12 13 14 16 17 18 19 20 21 22 23 24 33 34  
35 36 37 38  
chain bonds :

1-9 6-30 22-25 30-31 31-32 32-33  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 16-17 16-21  
17-18 18-19 19-20 19-22 20-21 20-24 22-23 23-24 33-34 33-38 34-35 35-36  
36-37 37-38  
exact/normal bonds :  
1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-30 16-17 16-21 17-18 18-19 19-20 19-22  
20-21 20-24 22-23 22-25 23-24 30-31 31-32 32-33  
normalized bonds :  
9-10 9-14 10-11 11-12 12-13 13-14 33-34 33-38 34-35 35-36 36-37 37-38  
isolated ring systems :  
containing 1 : 9 : 16 : 33 :

G1:C,N

G2:C,O,N

G3:C,S

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom  
23:Atom 24:Atom 25:CLASS 29:Atom 30:CLASS 31:CLASS 32:CLASS 33:Atom 34:Atom  
35:Atom 36:Atom 37:Atom 38:Atom

L1 STRUCTURE UPLOADED

=> D L1  
L1 HAS NO ANSWERS  
STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*  
Structure attributes must be viewed using STN Express query preparation.

=> S L1  
SAMPLE SEARCH INITIATED 13:17:59 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 564 TO ITERATE

100 08 PROCESSED 564 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00:00:01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: BATCH 9856 TO 12704  
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> S L1 SSS FULL  
FULL SEARCH INITIATED 13:18:04 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 11966 TO ITERATE

100 08 PROCESSED 11966 ITERATIONS 43 ANSWERS  
SEARCH TIME: 00:00:01

L3 43 SEA SSS FULL L1

=> FILE CAPLUS  
COST IN U.S. DOLLARS  
SINCE FILE TOTAL

FULL ESTIMATED COST

ENTRY SESSION  
166.94 167.36

FILE 'CAPLUS' ENTERED AT 13:18:08 ON 24 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2006 VOL 145 ISS 9  
FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L3  
L4 3 L3

=> D 1-3 IBI ABS HITSTR

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER:  
DOCUMENT NUMBER:  
TITLE:

Combinations of paroxetine and 2-(R)-(4-fluoro-2-methylphenyl)-4-(S)-((8a)-6-oxohexahydro-1,2-pyrazin-2-yl)piperidine-1-carboxylic acid  
1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethylmethylamide  
for treatment of depression/anxiety  
Melotto, Sergio; Corsi, Mauro; Carletti, Renzo  
Glaxo Group Limited, UK  
PCT Int. Appl., 25 pp.  
CODEN: PIKAD2

INVENTOR(S):  
PATENT ASSIGNEE(S):  
SOURCE:

DOCUMENT TYPE:  
LANGUAGE:  
FAMILY ACC. NUM. COUNT:  
PATENT INFORMATION:

RELATED CASE  
(NO U.S.)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091615	A1	20041028	WO 2004-EP4121	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BU, CF, CG, CI, CM, GA, GN, GQ, GW, HT, IL, IN, LU, NL, SE, SI, TD, TG				
EP 1615641	A1	20060118	EP 2004-739085	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, SI, PT,				

IE, SI, IT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
 PRIORITY APPL. INFO.:


AB GB 2003-8968 A 20030417  
 MO 2004-EP4121 W 20040416

The present invention relates to therapeutic combinations comprising  
 paroxetine or salts or solvates thereof and 2-(R)-(4-fluoro-2-  
 methylphenyl)-4-(S)-((8aS)-6-oxohexahydropyrrolo[1,2-a]pyrazin-2-  
 yl)piperidine-1-carboxylic acid [1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethyl]  
 piperidine-1-carboxylic acid [1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethyl]  
 comps. containing the combinations and their use in the treatment of  
 depression and/or anxiety. Thus, tablets contained paroxetine-HCl  
 hemihydrate 7.5, I-HCl 1, dibasic calcium phosphate 106.75, Mg stearate  
 1.5, Crospovidone 4.5, and colloidal silica 0.75 mg.  
 IT 579475-18-6 579475-21-1 781647-19-6  
 781647-20-9


RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USBS (Uses)  
 (combinations of paroxetine and (oxohexahydropyrrolopyrazinyl)piperidin  
 ecarboxylic acid (bistrifluoromethyl)ethylmethylamide for  
 treatment of depression/anxiety)

RN 579475-18-6 CAPLUS  
 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-  
 2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-  
 2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-21-1 CAPLUS  
 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-  
 2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-  
 2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




● HCl

RN 781647-19-6 CAPLUS  
 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-  
 2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-  
 2(1H)-yl]-N-methyl-, (2R,4S)-, mixt. with (3S,4R)-3-[(1,3-benzodioxol-5-  
 yloxy)methyl]-4-(4-fluorophenyl)piperidine (9CI) (CA INDEX NAME)

CM 1

CRN 579475-18-6  
 CMF C31 H35 F7 N4 O2


Absolute stereochemistry.



CM 2

CRN 61869-08-7  
 CMF C19 H20 F N O3

Absolute stereochemistry. Rotation (-).




RN 781647-20-9 CAPLUS  
 1-piperidinecarboxamide, N-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-  
 2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-  
 2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)-, mixt. with  
 (3S,4R)-3-[[1,3-benzodioxol-5-yl]oxy]methyl]-4-(4-fluorophenyl)piperidine  
 hydrochloride hydrate (2:1) (3CI) (CA INDEX NAME)

CM 1

CRN 579475-21-1  
 CMF C31 H35 F7 N4 O2 . C1 H

Absolute stereochemistry.




● HCl

CM 2

CRN 110429-35-1  
 CMF C19 H20 F N O3 . C1 H . 1/2 H2 O

Absolute stereochemistry. Rotation (-).



● HCl

● 1/2 H2O

REFERENCE COUNT: 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:  
 DOCUMENT NUMBER:  
 141:167799

TITLE:  
 Use of NK1 receptor antagonists for the treatment of  
 functional dyspepsia

INVENTOR(S):  
 Dukes, George Earl; Hicks, Gareth Andrew; Sanger,  
 Gareth John

PATENT ASSIGNEE(S):  
 Glaxo Group Limited, UK

SOURCE:  
 PCT Int. Appl., 16 pp.

DOCUMENT TYPE:  
 CODEN: PIXXD2

LANGUAGE:  
 Patent

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:  
 English

RELATED CASE  
 (NO V.S.)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067093	A2	20040812	WO 2004-EP752	20040126
WO 2004067093	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NP, NT, NZ, OM, PA, PE, PG, PH, PK, PL, PT, QA, RO, RU, RW, SA, SC, SD, SE, SG, SH, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, SZ, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VG, VI, VN, YU, ZA, ZM, ZW	A2	20051116	EP 2004-705094	20040126
R: AT, BE, BF, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, SK, SI, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK, JP 2006516581	T2	20060706	JP 2006-501644	20040126
PRIORITY APPLN. INFO.:				
			GB 2003-1841	A 20030127
			GB 2003-1842	A 20030127
			WO 2004-EP752	W 20040126

OTHER SOURCE(S):  
 MARPAT 141:167799

AB The present invention relates to the use of NK1 receptor antagonists for the treatment of functional dyspepsia (FD). For example, the use of NK1 receptor antagonists in the treatment of FD were supported by appropriate clin. trials in a double-blinded and placebo-matched study. Particularly the use of the compds. 2-((S)-1-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-1,3,5-bis(trifluoromethyl)phenyl]ethyl]methylamide and its methanesulfonate salt, and 2-methoxy-5-(5-trifluoromethyltetrazol-1-ylbenzyl)-(2S-phenylpiperidin-3S-yl)amine in the treatment of FD was


designed to elicit measurements relating to efficacy and safety across a range of three doses. The primary endpoint was adequate relief of FD pain or discomfort, secondary endpoint included (1) changes in daily upper abdominal pain severity ratings, (2) proportion of pain free days, (3) changes in self-ratings of nausea, early satiety, bloating or distension, postprandial fullness and burping or belching, and (4) changes in quality of life.

IT 579475-18-6 579475-21-1 579475-24-4  
733041-57-1

RL: THU (therapeutic use); BIOI (biological study); USES (uses)  
(NK1 receptor antagonists for treatment of functional dyspepsia)


RN 579475-18-6 CAPLUS  
CN 1-piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-21-1 CAPLUS  
CN 1-piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 579475-24-4 CAPLUS  
CN 1-piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 579475-18-6  
CMF C31 H35 F7 N4 O2


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 733041-57-1 CAPLUS  
CN 1-piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 579475-18-6  
CMF C31 H35 F7 N4 O2

Absolute stereochemistry.



CM 2  
CRN 75-75-2  
CMF C H4 O3 S


HO-S-CH3

14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2003:633712 CAPLUS  
DOCUMENT NUMBER: 139:180087  
TITLE: Preparation of pyrrolopyrazinylpiperidinecarboxamides as tachykinin antagonists.  
INVENTOR(S): Alvaro, Giuseppe; Di Fabio, Romano; Tranquillini, Maria Elvira; Spada, Simone  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: PCT Int. Appl., 65 pp.  
CODEN: PIKAD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066635	AI	20030814	WO 2003-EP1308	20030210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	AI	20030814	WO 2003-EP1308	20030210
RM: GH, GM, KE, LS, MM, MU, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, CA 2475619 AU 200305753 AU 2003-205753 20030210	AI	20030902	CA 2003-2475619	20030210
EP 1472256	AI	20041103	EP 2003-702621	20030210

EP 1472256 B1 20051102  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK, BR 2003007123 A 20041207  
CN 1628115 A 20050615  
US 2005176715 A1 20050811  
JP 2005524637 T2 20050818  
AT 308543 E 20051115  
ES 2250870 T3 20060416  
EP 1666465 A1 20060607  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, AL, TR, BG, CZ, EE, HU, SK, ZA 2004004842 A 20050726  
NO 2004003239 A 20040802  
PRIORITY APPLN. INFO.:  
MARPAT 139:180087  
OTHER SOURCE(S):  
GI

APPLICANTS



AB Title compds. [I: R = halo, C1-4 alkyl; R1 = C1-4 alkyl; R2, R3 = H, C1-4 alkyl; R4 = CF3, C1-4 alkyl, C1-4 alkoxy, OCF3, halo; R5 = H, C1-4 alkyl, C3-7 cycloalkyl; R6 = H, R7 = OH, or vice versa; X = CH2, NR5, O; Y = N, Z = CH, or vice versa; A = CO, SOq; when Y = N and Z = CH, A = SOq; m = 0-3; n = 1-3; p, q = 1, 2], were prepared. Thus, 2-(R)-(4-fluoro-2-methylphenyl)-4-oxopiperidine-1-carboxylic acid [3, 5-bis(trifluoromethyl)benzyl]methanamide (preparation given) and hexahydroindolizino[1,2-a]pyrazin-6-one (preparation given) were stirred 15 min. in MeCN; NaBH(OAc)3 was added and the mixture was stirred 2 days to give 2-(R)-(4-fluoro-2-methylphenyl)-4-(R)-(6-oxohexahydroindolizino[1,2-a]pyrazin-2-yl)piperidine-1-carboxylic acid [3, 5-bis(trifluoromethyl)benzyl]methanamide and 2-(R)-(4-fluoro-2-methylphenyl)-4-(S)-(6-oxohexahydroindolizino[1,2-a]pyrazin-2-yl)piperidine-1-carboxylic acid [3, 5-bis(trifluoromethyl)benzyl]methanamide. I showed NK1 receptor binding activity with pKi = 9.4-11.0. I pharmaceutical compns. are claimed.  
579475-21-IP 579475-23-3P  
IT RL: PKC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THO (Therapeutic use); BIOI (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrrolopyrazinylpiperidinecarboxamides as tachykinin antagonists)  
RN 579475-21-1 CAPLUS  
CN 1-piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8S)-hexahydro-6-oxo-2,3,4,5-tetrahydropyrazin-2-yl]-N-methyl-, monohydrochloride, (2R,4S)-(1S) (CA INDEX NAME)  
Absolute stereochemistry.




● HCl

RN 579475-23-3 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

● 2 H2O

PAGE 2-A


IT 579474-94-5P 579474-97-8P 579474-99-0P

579475-01-7P 579475-03-9P 579475-05-1P  
579475-07-3P 579475-09-5P 579475-11-9P  
579475-13-1P 579475-15-3P 579475-17-5P  
579475-18-6P 579475-20-0P 579475-24-4P  
579475-26-6P 579475-28-8P 579475-30-2P  
579475-31-3P 579475-33-5P 579475-35-7P  
579475-37-9P 579475-39-1P 579475-41-5P  
579475-43-7P 579475-45-9P 579475-48-2P  
579475-50-6P 579475-52-8P 579475-54-0P  
579475-56-2P 579475-57-3P 579475-59-5P  
579475-61-9P 579475-63-1P 579475-65-3P  
579475-13-4P 579475-16-7P  
RT: PKC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of pyrrolopyrazinylpiperidinecarboxamides as tachykinin antagonists)


RN 579474-94-5 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl)-N-methyl-, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579474-97-8 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl)-N-methyl-, (2R,4S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 579474-99-0 CAPUS  
CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-N-methyl-, monohydrochloride, (2R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 2-A


RN 579475-01-7 CAPUS  
CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-N-methyl-, (2R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-03-9 CAPUS  
CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-N-methyl-, (2R,4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 579475-05-1 CAPUS  
CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-N-methyl-, monohydrochloride, (2R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 579475-07-3 CAPLUS  
 CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 579475-09-5 CAPLUS


CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-11-9 CAPLUS  
 CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-13-1 CAPLUS  
 CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 579475-15-3 CAPJUS  
 CN 1-Piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8a)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 579475-17-5 CAPJUS


CN 1-Piperidinecarboxamide, N-([1R]-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-2-(4-fluoro-2-methylphenyl)-4-[(8a)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-18-6 CAPJUS  
 CN 1-Piperidinecarboxamide, N-([1R]-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-2-(4-fluoro-2-methylphenyl)-4-[(8a)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-20-0 CAPJUS  
 CN 1-Piperidinecarboxamide, N-([1R]-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-2-(4-fluoro-2-methylphenyl)-4-[(8a)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 579475-24-4 CAPIUS  
 1-piperidinecarboxamide, N-[(1R)-1-[(3,5-bis(trifluoromethyl)phenyl)ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 579475-18-6  
 CMF C31 H35 F7 N4 O2


Absolute stereochemistry.



CM 2


CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 579475-26-6 CAPIUS  
 1-piperidinecarboxamide, N-[(1R)-1-[(3,5-bis(trifluoromethyl)phenyl)ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-28-8 CAPIUS  
 1-piperidinecarboxamide, N-[(1R)-1-[(3,5-bis(trifluoromethyl)phenyl)ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-30-2 CAPIUS  
 1-piperidinecarboxamide, N-[(1R)-1-[(3,5-bis(trifluoromethyl)phenyl)ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 579475-31-3 CAPIUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 579475-33-5 CAPIUS  
CN 1-Piperidinecarboxamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-35-7 CAPIUS  
CN 1-Piperidinecarboxamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-37-9 CAPIUS  
CN 1-Piperidinecarboxamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-39-1 CAPUS  
 CN 1-Piperidinecarboxamide, N-[(1*S*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8*aR*)-hexahydro-6-oxopyrrolo[1,2-*a*]pyrazin-2(1*H*)-yl]-N-methyl-, (2*R*,4*S*)- (9*CI*) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-41-5 CAPUS  
 CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8*aS*)-hexahydro-6-oxopyrrolo[1,2-*a*]pyrazin-2(1*H*)-yl]-N-methyl-, (2*R*,4*R*)- (9*CI*) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-43-7 CAPUS  
 CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8*aS*)-hexahydro-6-oxopyrrolo[1,2-*a*]pyrazin-2(1*H*)-yl]-N-methyl-, (2*R*,4*S*)- (9*CI*) (CA INDEX NAME)


Absolute stereochemistry.



RN 579475-45-9 CAPUS  
 CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8*aS*)-hexahydro-6-oxopyrrolo[1,2-*a*]pyrazin-2(1*H*)-yl]-N-methyl-, monohydrochloride, (2*R*,4*R*)- (9*CI*) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 579475-48-2 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 2-A


RN 579475-50-6 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)

methyl-, (2R,4R)- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.



RN 579475-52-8 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 579475-54-0 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 2-A

RN 579475-56-2 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S) - (9CI) (CA INDEX NAME)  
Absolute stereochemistry.

PAGE 1-A




● HCl


PAGE 2-A

RN 579475-57-3 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-


yl]-N-methyl-, (2R,5S)-rel- (9CI) (CA INDEX NAME)  
Relative stereochemistry.



RN 579475-59-5 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2S,5S)-rel- (9CI) (CA INDEX NAME)  
Relative stereochemistry.



RN 579475-61-9 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2S,5S)-rel- (9CI) (CA INDEX NAME)  
Relative stereochemistry.




● HCl

RN 579475-63-1 CAPLUS


CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 579475-65-3 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl

RN 579476-13-4 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl]-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl)-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579476-16-7 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> LOG HOLD		SINCE FILE	
COST IN U.S. DOLLARS		ENTRY	
FULL ESTIMATED COST		15.79	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		SINCE FILE	
CA SUBSCRIBER PRICE		ENTRY	
		-2.25	
SESSION WILL BE HELD FOR 60 MINUTES		TOTAL	
STN INTERNATIONAL SESSION SUSPENDED AT 13:18:33 ON 24 AUG 2006		183.15	
		-2.25	